Abbott Laboratories (ABT) Q4 2025 (USD): Adj. EPS 1.50 (exp. 1.50), Revenue 11.46bln (exp. 11.80bln)

Abbott Laboratories reported Q4 2025 adjusted EPS in line with expectations but missed on revenue, which could raise concerns about demand or pricing power relative to market estimates.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

GE Aerospace (GE) CEO says no structural trade off between MRO support and new engine production - conference call

Procter & Gamble (PG) CFO anticipates Q2 would be the softest quarter of FY26; P&G currently below typical volume growth target of 3-4% across categories in the US

Abbott Laboratories (ABT) Q4 2025 (USD): Adj. EPS 1.50 (exp. 1.50), Revenue 11.46bln (exp. 11.80bln)

NATO's top commander says one of more concerning things in Arctic has been increased cooperation between China and Russia

NATO's Military Committee Chair says are waiting for direction on possible Greenland agreement

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

Guidance:

  • Q1 adj. EPS 1.12-1.18 (exp. 1.20).
  • FY adj. EPS 5.55-5.80 (exp. 5.68).
Context

Their Q1 and full-year guidance also falls short, suggesting potential headwinds ahead and may impact investor sentiment towards the stock and sector. Monitoring price action and peer performance will be important as analysts recalibrate their outlook based on this performance.

Related headlines

The whole workspace, free to try.

Try it free